| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | DRAL; AAG11; FHL-2; SLIM3; SLIM-3 |
| WB Predicted band size | 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human FHL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及FHL2抗体的文献概述(注：文献为模拟示例，实际引用需核实)：
---
1. **文献名称**：*FHL2 interacts with EGFR to promote tumor progression in triple-negative breast cancer*
**作者**：Li X, et al.
**摘要**：研究通过免疫共沉淀(Co-IP)和Western blot技术，发现FHL2蛋白与EGFR在乳腺癌细胞中直接结合。使用FHL2抗体检测其在肿瘤组织中的高表达，并证实FHL2通过激活EGFR信号通路促进肿瘤侵袭。
---
2. **文献名称**：*FHL2 regulates cardiac hypertrophy via modulating NF-κB signaling*
**作者**：Wang Y, et al.
**摘要**：利用FHL2特异性抗体进行免疫组化(IHC)和免疫荧光(IF)分析，发现FHL2在小鼠心脏肥厚模型中表达上调。研究揭示FHL2通过抑制NF-κB通路减轻心肌细胞肥大，提示其作为心脏疾病治疗靶点。
---
3. **文献名称**：*Prognostic significance of FHL2 expression in colorectal cancer*
**作者**：Zhang R, et al.
**摘要**：通过组织微阵列和FHL2抗体免疫组化染色，分析结直肠癌患者样本。结果表明，FHL2高表达与患者不良预后相关，并可能通过调控Wnt/β-catenin通路促进转移。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词“FHL2 antibody”或“FHL2 immunohistochemistry”，并筛选近五年高被引研究。
The FHL2 (Four and a Half LIM Domains 2) antibody is a crucial tool for studying the FHL2 protein, a member of the LIM-only protein family involved in diverse cellular processes. FHL2. characterized by four LIM domains and a half LIM motif, acts as a scaffold or adaptor protein, mediating protein-protein interactions in signaling pathways. It regulates gene expression, cell proliferation, apoptosis, and differentiation by interacting with transcription factors (e.g., β-catenin, androgen receptor), kinases, and structural proteins. FHL2 exhibits tissue-specific expression, with high levels in the heart, ovary, and prostate, and plays roles in cancer progression, cardiovascular disease, and musculoskeletal disorders.
FHL2 antibodies are widely used in research to detect endogenous FHL2 protein in applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate FHL2’s dual role as both a tumor suppressor and promoter, depending on cellular context. For instance, FHL2 suppresses Wnt/β-catenin signaling in some cancers but enhances androgen receptor activity in prostate cancer. Its involvement in fibrosis, hypertrophy, and mechanotransduction pathways further underscores its biomedical relevance. Commercial FHL2 antibodies are typically validated for specificity across human, mouse, and rat samples, enabling cross-species studies. Ongoing research focuses on FHL2’s potential as a therapeutic target or biomarker, particularly in cancers and cardiovascular diseases.
×
